DORCHESTER WEALTH MANAGEMENT Co grew its position in Pfizer Inc. (NYSE:PFE) by 0.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 149,272 shares of the biopharmaceutical company’s stock after buying an additional 440 shares during the period. Pfizer accounts for approximately 1.6% of DORCHESTER WEALTH MANAGEMENT Co’s investment portfolio, making the stock its 23rd largest holding. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Pfizer were worth $5,848,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in PFE. Kanawha Capital Management LLC increased its stake in Pfizer by 3.0% in the 2nd quarter. Kanawha Capital Management LLC now owns 188,839 shares of the biopharmaceutical company’s stock worth $8,180,000 after purchasing an additional 5,475 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Pfizer by 986.1% in the second quarter. Victory Capital Management Inc. now owns 1,173,830 shares of the biopharmaceutical company’s stock worth $50,850,000 after acquiring an additional 1,065,754 shares in the last quarter. Outlook Wealth Advisors LLC purchased a new position in shares of Pfizer in the second quarter worth approximately $206,000. Worldquant Millennium Advisors LLC increased its position in shares of Pfizer by 71.0% in the second quarter. Worldquant Millennium Advisors LLC now owns 234,900 shares of the biopharmaceutical company’s stock worth $10,176,000 after acquiring an additional 97,530 shares in the last quarter. Finally, Toroso Investments LLC acquired a new stake in shares of Pfizer during the second quarter valued at approximately $195,000. Institutional investors own 70.22% of the company’s stock.
PFE has been the topic of several research reports. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Royal Bank of Canada began coverage on shares of Pfizer in a research report on Monday, January 6th. They issued an “outperform” rating and a $46.00 price target on the stock. Credit Suisse Group restated a “hold” rating and issued a $41.30 price objective on shares of Pfizer in a research note on Wednesday, November 6th. Finally, Bank of America assumed coverage on shares of Pfizer in a report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price objective for the company. Nine analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $43.41.
Shares of NYSE:PFE opened at $40.34 on Wednesday. The business has a 50 day moving average price of $39.14 and a 200 day moving average price of $38.09. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $44.56. The company has a market cap of $224.19 billion, a price-to-earnings ratio of 14.10, a PEG ratio of 4.24 and a beta of 0.65. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.13. The firm had revenue of $12.68 billion for the quarter, compared to analyst estimates of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The company’s revenue was down 4.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.78 EPS. Analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be given a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 3.77%. This is a boost from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, January 30th. Pfizer’s dividend payout ratio is currently 48.00%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: What is a stock buyback?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.